Form 4: Abeona Therapeutics Director Leila Alland Acquires Shares
SEC Form 4
Director Leila Alland acquired 23,611 shares of Abeona Therapeutics common stock on July 8, 2024.
Summary
- On July 8, 2024, Leila Alland, a director of Abeona Therapeutics Inc., acquired 23,611 shares of common stock.
- The shares were acquired at a price of $0.00.
- Following the transaction, Alland directly owns 106,468 shares of Abeona Therapeutics Inc.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of a stock transaction by a company director. It doesn't inherently indicate positive or negative sentiment.
Future Outlook
The restricted stock acquired will vest on July 8, 2025.
Industry Context
Form 4 filings are standard disclosures required by the SEC when insiders such as directors and officers trade in their company's stock. These filings provide transparency to the market regarding insider activity.
Stakeholder Impact
- The acquisition of shares by a director could be perceived positively by shareholders, signaling confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 07/08/2024 | Date of transaction: Leila Alland acquired shares of common stock. |
| 07/08/2025 | Vesting date for restricted stock. |
| 07/09/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.